Dolby Laboratories, Inc.: Form 10-Q for the period ended Jun 27, 2014
Filed with the SEC on Jul 30, 2014 and accepted by EDGAR at Jul 30, 2014, 20:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-06-27. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-03-29 to 2014-06-27 | $223.3m | us-gaap:Revenues |
| Revenue | 9 months2013-09-28 to 2014-06-27 | $733.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-03-29 to 2014-06-27 | $18.9m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2013-09-28 to 2014-06-27 | $57.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-03-29 to 2014-06-27 | $204.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2013-09-28 to 2014-06-27 | $675.5m | us-gaap:GrossProfit |
| Research and development | 3 months2014-03-29 to 2014-06-27 | $46.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2013-09-28 to 2014-06-27 | $136.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-03-29 to 2014-06-27 | $50.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2013-09-28 to 2014-06-27 | $215.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-03-29 to 2014-06-27 | $251.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2013-09-28 to 2014-06-27 | $456.0k | us-gaap:InterestExpense |
| Income tax | 3 months2014-03-29 to 2014-06-27 | $11.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2013-09-28 to 2014-06-27 | $53.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-03-29 to 2014-06-27 | $39.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2013-09-28 to 2014-06-27 | $160.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-03-29 to 2014-06-27 | $0.38 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2013-09-28 to 2014-06-27 | $1.55 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-03-29 to 2014-06-27 | $0.39 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2013-09-28 to 2014-06-27 | $1.57 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-03-29 to 2014-06-27 | 103,942,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2013-09-28 to 2014-06-27 | 103,605,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2013-09-28 to 2014-06-27 | $272.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2013-09-28 to 2014-06-27 | $37.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2013-09-28 to 2014-06-27 | $0 | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2014-03-29 to 2014-06-27 | $29.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Share repurchases | 9 months2013-09-28 to 2014-06-27 | $41.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2014-06-27 | $590.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-06-27 | $987.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-06-27 | $1.94bn | us-gaap:Assets |
| Current liabilities | At period end2014-06-27 | $185.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-06-27 | $252.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-06-27 | $1.66bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001445305-14-003111. Last ingested by Listed: Nov 14, 2026, 23:59 ET. Listed shows no prices and gives no investment advice.